Skip to main content

Skelid Side Effects

Generic name: tiludronate

Medically reviewed by Last updated on Nov 16, 2023.

Note: This document contains side effect information about tiludronate. Some dosage forms listed on this page may not apply to the brand name Skelid.

Applies to tiludronate: oral tablet.


Take tiludronate with a full glass (6 to 8 ounces) of water. Use only plain water (not mineral water) when taking a tiludronate tablet.

For at least the first 2 hours after taking tiludronate, do not eat or drink anything other than plain water, and do not take any other medicines including vitamins or mineral supplements.

Especially avoid drinking milk or eating dairy products within 2 hours after taking tiludronate. Also avoid taking supplements that contain calcium, magnesium, iron, or aluminum (such as in multivitamins with iron, and in many types of antacids).

Some people using medicines similar to tiludronate have developed bone loss in the jaw, also called osteonecrosis of the jaw. Symptoms may include jaw pain, swelling, numbness, loose teeth, gum infection, or slow healing after injury or surgery involving the gums. You may be more likely to develop osteonecrosis of the jaw if you have cancer or have been treated with chemotherapy, radiation, or steroids. Other conditions associated with osteonecrosis of the jaw include blood clotting disorders, anemia (low red blood cells), and a pre-existing dental problem.

If you need to have any dental work (especially surgery), tell the dentist ahead of time that you are using tiludronate. You may need to stop using the medicine for a short time.

Talk with your doctor about the risks and benefits of using this medication.

Get emergency medical help if you have any of these signs of an allergic reaction while taking tiludronate (the active ingredient contained in Skelid) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using tiludronate and call your doctor at once if you have any of these serious side effects:

Less serious side effects of tiludronate may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to tiludronate: oral tablet.


The most frequently occurring adverse reactions reported were: Diarrhea (9.3%), nausea (9.3%), and dyspepsia (5.3%).[Ref]


Common (1% to 10%): Hypertension, flushing[Ref]


Common (1% to 10%): Rash, skin disorder, pruritus, increased sweating[Ref]


Common (1% to 10%): Hyperparathyroidism[Ref]


Common (1% to 10%): Diarrhea, nausea, dyspepsia, vomiting, flatulence, tooth disorder, abdominal pain, constipation, dry mouth gastritis[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Common (1% to 10%): Vitamin D deficiency, anorexia[Ref]


Bone, joint, and/or muscle pain, rarely severe and/or incapacitating have been reported.[Ref]

Common (1% to 10%): Arthralgia, back pain, arthrosis, fracture pathological, skeletal pain

Postmarketing reports: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, including this drug[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, paresthesia, vertigo, involuntary muscle contractions, somnolence, nervousness[Ref]


Common (1% to 10%): Cataract, conjunctivitis, glaucoma[Ref]


Common (1% to 10%): Pain, accidental injury, influenza like symptoms, chest pain, peripheral edema, infection, asthenia, syncope, fatigue[Ref]


Common (1% to 10%): Insomnia, anxiety[Ref]


Common (1% to 10%): Rhinitis, sinusitis, upper respiratory tract infection, coughing, pharyngitis, bronchitis[Ref]


Rare (less than 0.1%): Stevens-Johnson syndrome[Ref]


1. Product Information. Skelid (tiludronate). Sanofi Winthrop Pharmaceuticals. PROD.

2. Lourwood DL. The pharmacology and therapeutic utility of bisphosphonates. Pharmacotherapy. 1998;18:779-89.

3. Cerner Multum, Inc. UK Summary of Product Characteristics.

4. Cerner Multum, Inc. Australian Product Information.

5. Roux C, Listrat V, Villette B, Lessana-Leibowitch M, Ethgen D, Pelissier C, Dougados M, Amor B. Long-lasting dermatological lesions after tiludronate therapy. Calcif Tissue Int. 1992;50:378-80.

6. Reginster JY, Lecart MP, Deroisy R, Ethgen D, Zegels B, Franchimont P. Paget's disease of bone treated with a five day course of oral tiludronate. Ann Rheum Dis. 1993;52:54-7.

7. Fraser WD, Stamp TC, Creek RA, Sawyer JP, Picot C. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J. 1997;73:496-502.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.